BioAge Labs, Inc. Common Stock
BIOABioAge Labs, Inc. is a biotechnology company focused on developing therapies to target aging and age-related diseases. Leveraging insights from aging biology, it aims to extend healthspan and improve quality of life by identifying and modulating molecular pathways involved in aging processes.
Company News
Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.
BioAge Labs will present at the Jefferies Global Healthcare Conference in London, with CEO Kristen Fortney and CFO Dov Goldstein participating in a fireside chat and one-on-one meetings, discussing their clinical-stage biotechnology work on metabolic disease therapies.
BioAge Labs' stock jumped 46.6% after a Citigroup analyst upgraded its rating to buy, citing potential for its experimental weight management drug BGE-102 that targets brain inflammation and appetite regulation.
BioAge Labs, a clinical-stage biopharmaceutical company, announced the closing of its initial public offering and concurrent private placement, raising approximately $238.3 million in gross proceeds.
